



S **SYSCHEM**
INDIA

INVESTOR PITCH DECK

~INNOVATING TODAY FOR A HEALTHIER TOMORROW

AGENDA

Corporate Identity

03-10

Production

11-13

Financials

14-22

Governance & Sustainability

24-33



CORPORATE IDENTITY

www.syschem.in

Syschem (India) Limited (SIL) is a listed company engaged in the manufacturing of Bulk Drugs/Intermediates and contract manufacturing. It is owned and operated by a highly committed group of techno commercial with extensive experience in the bulkdrug business.

The Company is committed to its highly committed team of techno-commercial specialists with considerable expertise in the bulk medicine market. Syschem India Limited has established a firm presence in the business by providing their consumers with high-quality products and services.

The Company's commitment to research and development, quality assurance, and customer satisfaction has established it as a trusted partner in the pharmaceutical business.





The company aims to become one of India's leading manufacturers of APIs and pharmaceutical intermediates by creating long-term value for all stakeholders through innovation, operational excellence, and responsible manufacturing. It is committed to fostering a culture of collaboration, growth, and safety at every level while continuously investing in R&D and quality systems to meet evolving customer and regulatory requirements. The organization also strives to adopt sustainable practices and minimize its environmental impact across the entire value chain.



To become a leading and trusted global partner in the API industry by providing high-quality, innovative, and sustainable solutions. Syschem India Limited is committed to scientific excellence, regulatory compliance, and creating long-term value for customers, employees, and society through ethical and environmentally responsible practices.

Reliable Supply

Syschem India Limited operates a resilient and scalable supply chain backed by integrated manufacturing, disciplined capacity planning, and strong vendor partnerships. This enables the company to deliver critical APIs consistently across domestic and global markets, ensuring reliability even in volatile industry conditions.

World Class Quality

Quality excellence is embedded in Syschem's operating DNA. With internationally aligned manufacturing standards, advanced analytical laboratories, and rigorous compliance systems, the company delivers APIs that meet the strictest global regulatory and customer requirements.

Continuous Innovation

Syschem drives sustainable growth through continuous investments in R&D, process engineering, and product development. By enhancing process efficiency, expanding its product portfolio, and adopting advanced technologies, the company stays ahead of market trends and customer expectations.

Customer Engagement

Syschem India Ltd. focuses on building strong customer relationships through quality products, timely deliveries, and reliable service, ensuring long-term trust and client satisfaction. The company continuously works towards enhancing customer retention and expanding its global client network.



Operational Infrastructure & Scalability

Market Reach & Geographic Expansion

Leadership Capability & Strategic Direction

Financial Strength & Sustainability



- INSTALLED CAPACITY OF ~ 4200 TPA
- 6+ ACRES LAND BANK AREA
- DRIVING THE STRATEGIC EXPANSION OF EXISTING FACILITIES THROUGH BACKWARD INTEGRATION TO ENHANCE CAPACITY, EFFICIENCY, AND LONG-TERM GROWTH.

- 200+ CONSUMERS AND TRADERS GLOBALLY
- 7+ API SKUs
- GLOBAL FOOTPRINT: 3 CONTINENTS. AND 12+ COUNTRIES

SIL IS LED BY AN EXPERIENCED MANAGEMENT TEAM WITH PROFICIENCY OF OVER 3 DECADES AND SUPPORTS THE BUSINESS IN IDENTIFYING AND SEIZING GROWTH OPPORTUNITIES THAT WILL LIKELY ARISE AS A RESULT OF CHANGES IN DEMAND OF APIS.

- REVENUE GROWTH OF 70% IN COMPARISON TO LAST FINANCIAL YEAR
- EBITDA growth of 423% IN COMAPRISON TO LAST FINANCIAL YEAR.
- PAT growth of APROXX 2276% IN COMAPRISON TO LAST FINANCIAL YEAR.



MANUFACTURING EXPANSION

Development of dedicated Amoxicillin and other products like Cloxacillin sodium , Flucloxacillin sodium and Dicloxacillin sodium plants to enhance manufacturing capacity and support future business growth.



WORKFORCE GROWTH

Employee strength increased by 17%, supporting operational expansion and organizational development.



QUALITY COMPLIANCE

Focused on achieving WHO-GMP certification to strengthen global quality standards and regulatory compliance.


OUR KEY PRODUCTS



01

Amoxicillin T/H

Amoxicillin is a widely used antibiotic belonging to the penicillin group of antibiotics.



02 Ampicillin T/H

Ampicillin is a type of antibiotic that is commonly used to treat bacterial infections.



03

Flucloxacillin Sod.

Flucloxacillin is a type of antibiotic that is commonly used to treat bacterial infections



04

Cloxacillin Sod.

Cloxacillin is a type of antibiotic that is commonly used to treat bacterial infections.



05

Cephalexin


Cephalexin is a type of antibiotic that is commonly used to treat bacterial infections.




06

Cephadroxil

Cephadroxil is a type of antibiotic that belongs to the cephalosporin family. It works by inhibiting the growth of bacteria and preventing them from reproducing.



SUPPLY ZONE



The Company has a diverse range of APIs in the pharmaceuticals industry that are created chemically. The company has established a foothold in India and the international market.


Syschem's expansive supply chain network is a testament to its commitment to excellence and reliability. Operating across 14+ Indian states and reaching over ten international locations, Syschem has established itself as a formidable player in the global market. This extensive reach ensures that the company can efficiently meet the diverse needs of its customers, maintaining a seamless flow of high-quality products.



Expanding operations and improving customer satisfaction are core goals for any thriving business. As we continue to grow, our focus remains on understanding and anticipating the needs of our customers, ensuring that we deliver unparalleled service and quality. This expansion involves not just increasing our geographical footprint, but also enhancing our product offerings and service channels to be more accessible and innovative.



 **Top 12 Export Destinations**



PRODUCTION

www.syschem.in



FY 25-26



QUARTER 1



QUARTER 2



QUARTER 3



QUARTER 4

Syschem India Ltd. demonstrated strong operational momentum with production volumes increasing from 463 MT in Q1 to 1,239 MT in Q4, reflecting significant capacity ramp-up and enhanced manufacturing efficiency throughout the fiscal year.

PRODUCTION FY 24-25 v/s FY 25-26



FY 24-25



FY 25-26


6,795.75 09:30 09:55 10:08 10:30 11:15 11:48 12:06

CWQT	▲	99.0	+99.0%
BOTJ	▼	-0.82	-0.82%
TRE	▼	-32.0	-32.0%
	▲	+75.0	+75.0%
	▼	-34.0%	
	▲	-56	
	▼	-65.0	
	▲	+83	

FINANCIALS

www.syschem.in





655 Cr.
TOTAL REVENUE

21.11 Cr.
EBITDA

17.08 Cr.
YOY EBITDA GROWTH

10.93 Cr.
PAT


FY 25-26

Syschem India Ltd. achieved a robust financial performance with ₹655 Cr in revenue, ₹21.11 Cr EBITDA, and ₹10.93 Cr PAT, reflecting strong operational execution and sustained profitability growth, further strengthening the company's financial position and reinforcing its long-term growth trajectory.

SALES PREVIOUS V/S CURRENT FISCAL YEAR


FY24-25

Figures in Rs.Lakhs



FY25-26


Figures in Rs.Lakhs



Syschem India Limited delivered strong growth in FY 2025–26, with sales rising from ₹38623 lakhs in FY 2024–25 to ₹65462 lakhs in FY 2025–26, representing a robust **70% year-on-year increase**. This sharp expansion across the year highlights accelerating demand and the company's improving market traction.


DOMESTIC V/S EXPORT

Figures in Rs.Lakhs



2025

Export SALES :- **19839 Lacs**
Domestic SALES :- **45622 Lacs**




2024

Export SALES :- **9089 Lacs**
Domestic SALES :- **24125 Lacs**


Syschem India Limited delivered strong performance in FY 2025-26, with export sales of ₹198.39 crore exceeding the full-year FY 2024-25 exports of ₹90.890 crore. Domestic sales also rose to ₹456.22 crore in 9M FY 2025-26 compared to ₹241.25 crore in FY 2024-25, demonstrating robust demand and strong execution across both markets.

Figures in Rs.Lakhs




FY 24-25

- Q1
PAT :- **13.67**
- Q2
PAT :- **-64.01**
- Q3
PAT :- **50.31**
- Q4
PAT :- **46.00**



FY 25-26


- Q1
PAT :- **167.35**
- Q2
PAT :- **189.84**
- Q3
PAT :- **417.08**
- Q4
PAT :- **174**



- FY 24-25**
PAT :- **46.00**
- FY 25-26**
PAT :- **1093**


The Company recorded a healthy Profit Before Tax (PBT) during the year, primarily driven by improved operational performance and ongoing capital expenditure (Capex) expansion initiatives undertaken to enhance existing facilities and support future growth. However, the Profit After Tax (PAT) for the quarter appears comparatively lower than the previous quarter due to the impact of deferred tax adjustments recognized during the last quarter of the financial year. The deferred tax provision, arising from Capex-related accounting treatments and timing differences, has temporarily affected the net profitability figures, despite the Company maintaining strong underlying business fundamentals and growth momentum.

Figures in Rs.Lakhs




FY 24-25

- Q1 EBITDA : 81.86
- Q2 EBITDA :- 6.88
- Q3 EBITDA :-122.1
- Q4 EBITDA :-191.66



FY 25-26

- Q1 EBITDA :- 246.93
- Q2 EBITDA :- 331.36
- Q3 EBITDA :- 596.32
- Q4 EBITDA :-936.74



FY 24-25

- EBITDA :- 403.2
- EBITDA MARGIN% : 1.04%

FY 25-26

- EBITDA :- 2111.4
- EBITDA MARGIN% : 3.22%

2024


FY24-25

SALES :- **38623 Lacs**

2025

FY25-26

SALES :- **65462 Lacs**



Figures in Rs.Lakhs

Syschem India Ltd. delivered strong topline growth, with revenue increasing from **₹386.23 Cr** in **FY 2024-25** to **₹654.62 Cr** in **FY 2025-26**, reflecting significant business expansion and enhanced market traction. The growth highlights the company's strengthening operational scale and rising industry presence.



Revenue Expansion

Company recorded a strong 70% increase in revenue in FY 2025–26 compared to FY 2024–25, reflecting rapid scale-up in operations, stronger customer demand, and expanded market reach across domestic and export segments.


01



PBT Surge

PBT grew by an exceptional 1361% in FY 25-26 in comparison of FY 24-25 highlighting sharp improvement in operating leverage, cost control, and financial discipline, which significantly strengthened the company's earnings quality.

03



EBITDA Growth

EBITDA surged by 423%, driven by higher volumes, improved product mix, and enhanced operating efficiencies, demonstrating Syschem's ability to convert revenue growth into superior operating profitability.

02



Profits Trending Up

PAT increased by an outstanding 2276%, in comparison to last financial year reflecting strong margin expansion and efficient capital utilization, positioning Syschem for sustained profitability going forward.

04

BALANCE SHEET

Figures in Rs.Lakhs

Financial Performance Comparison:

*Q4 FY 2025-26 marks a defining quarter for Syschem India Limited, with exceptional growth across all key financial metrics. Strong demand, improved capacity utilization, and disciplined cost management drove a **78.9%** increase in revenue, while operating leverage translated this into a **329%** rise in EBITDA and a **453%** growth in PBT. This performance reflects the strength of our strategy, the resilience of our business model, and our ability to convert growth into sustainable profitability.*

Particulars	Q4 FY24-25	Q4 FY25-26	YoY% incr.	Q3 FY24-25	Q3 FY25-26	YoY% incr.
Revenue From Operations	13875	24830.19	78.9%	9112.6	16164	77%
EBITDA	191.66	936.74	389%	122.05	596.32	388%
EBITDA Margin%	1%	3.30%	230%	1%	3.7%	270%
Other Income	1.60	0.36		1.62	0.161	
Depreciation & Amortization	90.97	172.51		67.95	82.44	
Finance Cost	-0.49	204.12		3.79	17.35	
PBT Before Exceptional Items	101.2	560.12		50.31	496.52	
Exceptional Items				0	0	
PBT	101.2	560.12	453%	50.31	496.52	886%
Tax Expense	55.15	355.9		0	79.44	
PAT	46.03	174.13	278.2%	50.31	417.08	729%
PAT Margin%	0.3%	0.73%	143%	0.6%	2.6%	333%
Average weighted EPS		0.40			0.96	
Diluted EPS		0.31			0.74	

BALANCE SHEET

Figures in Rs.Lakhs

Particulars	Q3 FY25-26	Q4 FY25-26	QoQ% incr.	FY24-25	FY25-26	YoY% incr.
Revenue From Operations	16164	24830.19	53.6%	38624	65464.70	70%
EBITDA	596.32	936.74	38%	403.2	2111.38	423%
EBITDA Margin%	3.7%	3.77%	1.8%	1.043%	3.22%	210%
Other Income	0.161	0.36		4.24	2.1	
Depreciation & Amortization	82.44	172.51		294.7	406.3	
Finance Cost	17.35	204.12		6.60	226.35	
PBT Before Exceptional Items	496.52	560.12		101.17	1478.8	
Exceptional Items	0					
PBT	496.52	560.12	12.8%	101.17	1478.8	1361%
Tax Expense	79.44	355.9		55.15	355.9	
PAT	417.08	174.28	-58.21%	46.00	1093	2276%
PAT Margin%	2.6%	0.7%	-71%	0.12%	1.67%	1291%
Average weighted EPS	0.96	0.40		0.115	2.50	
Diluted EPS	0.74	0.31		0.109	1.93	

GOVERNANCE & SUSTAINABILITY





www.syschem.in

CLIENTELE







E Environment



- Zero Liquid Discharge (ZLD) 
- Carbon Footprint Reduction 
- Eco-friendly Packaging 
- Efficient Utilities & Green Technologies 





S Social



- Healthcare Initiatives 
- Woman Empowerment 
- Fair Trade Practices 
- Gender Diversity 

G Governance



- Stakeholder Responsibility 
- Risk Management Governance 
- Adherence to Regulatory Compliance 
- Board Composition and Governance 

RANJAN JAIN

MANAGING DIRECTOR

With over 25+ years of entrepreneurial experience. Mr. Jain has led Syschem's strategic diversification and growth in the pharmaceutical and chemical domain.

SUNINDER VEER SINGH

WHOLE-TIME DIRECTOR

He oversees Sales and Marketing, bringing over two decades of extensive experience across both national and international markets, and plays a key role in driving the company's commercial strategy and growth.

SANJEEV AGRAWAL

CHIEF FINANCIAL OFFICER

With around 30 years of experience in finance, operations, and business development, he plays a key role in Strategic financial decision-making Optimizing capital structure.


~ INNOVATING TODAY FOR A HEALTHIER TOMORROW

Shareholding Pattern as on 31st March, 2026

Particulars	% Shareholding
Promoter and Promoter Group	60.86%
Public	39.14%
TOTAL	100%

Market Indicators


Incorporated	1991
Listed on	BSE
BSE Scrip Code NSE Symbol	531173 SYSCHEM
Issued Shares	4,90,13,000
Paid up Capital (Rs. Lakhs)	4901.30 lakhs
52 Weeks High/Low	62/40.55



SAFE HARBOUR STATEMENT

This Information Memorandum has been prepared by the Company based on information and data which the Company considers reliable. However, the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, reliability, or fairness of the contents of this Presentation. This Presentation may not be all-inclusive and may not contain all the information that you may consider material. Any liability in respect of the contents of or any omission from this Presentation is expressly excluded. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Presentation or in relation to the bases and assumptions underlying such projections. You must satisfy yourself in relation to the reasonableness, achievability, and accuracy thereof.

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and assumptions that are difficult to predict.



These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the wind power industry in India and worldwide, the Company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences, and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance, or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company, and the Company is not responsible for such third-party statements and projections.

No responsibility or liability is accepted for any loss or damage, howsoever arising, that you may suffer as a result of this Presentation. All responsibility and liability are expressly disclaimed by the Management, the Shareholders, and the Company or any of them or any of their respective directors, officers, affiliates, employees, advisers, or agents.





~ INNOVATING TODAY FOR A HEALTHIER TOMORROW

THANK YOU

For further information contact

www.syschem.in

Head Office : 825, FF, NAC Manimajra ,
Chandigarh-161001

Factory at : Village Bargodam, Tehsil Kalka,
Dist. Panchkula, Haryana-133302



0172-5070471



info@syschem.in